Addressing a preliminary injunction in patent litigation related to the Biologics Price Competition and Innovation Act (BPCIA), the US Court ...

On January 29, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court for the Northern District of West ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European ...

Shares in US retinal diseases specialist EyePoint Pharmaceuticals recovered from an early nosedive to close trading marginally higher on Wednesday.

EyePoint Pharmaceuticals, Inc. (EYPT) is up by 3.66 percent during Monday trading, rising $0.28 to $7.90. The stock moved higher ...

EyePoint (EYPT) stock rose 10% after the company reported six-month results from a phase 2 study of its drug Duravyu in the treatment of diabetic macular edema. Read more here.

(RTTNews) - EyePoint Pharmaceuticals, Inc. (EYPT), Wednesday announced positive six-month results from the ongoing Phase 2 VERONA clinical trial, evaluating Duravyu for the treatment of diabetic ...

WATERTOWN, Mass. - EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT), currently valued at $535 million, announced positive results from the Phase 2 VERONA clinical trial of DURAVYU™, its ...

Despite these positive outcomes, EyePoint's stock experienced a sharp decline. Cantor Fitzgerald analyst Jennifer Kim commented on the market reaction, stating, "There's nothing here that makes us ...

Investing.com -- Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ: EYPT) fell 21% today, diverging from the company's recent announcement of positive results from the Phase 2 VERONA clinical ...

AgreementLotus Pharmaceutical becomes strategic partner for the commercialization of Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® in the Asia-Pacific Region 05.02.2025 / 06:30 CET/CESTThe issuer is ...